Bausch Health Canada announces CABTREO availability via public drug plans

Bausch Health (BHC), Canada announced that CABTREO gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris is now available to beneficiaries of the public drug plans of Ontario and Nova Scotia as well as through the federal government’s Non-Insured Health Benefits drug plan for Indigenous populations and that of the Correctional Service of Canada.